NASDAQ:CGTX Cognition Therapeutics (CGTX) Stock Price, News & Analysis $0.88 -0.02 (-2.04%) Closing price 04:00 PM EasternExtended Trading$0.88 0.00 (-0.22%) As of 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Cognition Therapeutics Stock (NASDAQ:CGTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cognition Therapeutics alerts:Sign Up Key Stats Today's Range$0.87▼$0.9250-Day Range$0.89▼$1.1352-Week Range$0.55▼$2.05Volume315,826 shsAverage Volume1.03 million shsMarket Capitalization$83.38 millionP/E RatioN/ADividend YieldN/APrice Target$3.33Consensus RatingModerate Buy Company Overview Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for neurodegenerative diseases that affect memory, cognition and behavior. The company’s research centers on drug candidates designed to protect or restore synaptic function, which is important for communication between nerve cells. Cognition Therapeutics’ lead investigational product is CT1812, an orally administered, brain-penetrant small molecule designed to modulate the sigma-2 receptor complex. The company is evaluating CT1812 as a potential treatment for Alzheimer’s disease and dementia with Lewy bodies, including through clinical studies intended to assess its effects on cognition and disease-related biological processes. The company’s programs remain investigational, and CT1812 has not been approved for commercial use. Cognition Therapeutics conducts its development activities through clinical research programs and collaborations primarily focused on neurodegenerative diseases in the United States and other study locations.AI Generated. May Contain Errors. Read More Cognition Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreCGTX MarketRank™: Cognition Therapeutics scored higher than 34% of companies evaluated by MarketBeat, and ranked 725th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingCognition Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCognition Therapeutics has a consensus price target of $3.33, representing about 281.0% upside from its current price of $0.88.Amount of Analyst CoverageCognition Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Cognition Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cognition Therapeutics are expected to grow in the coming year, from ($0.30) to ($0.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cognition Therapeutics is -5.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cognition Therapeutics is -5.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCognition Therapeutics has a P/B Ratio of 2.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cognition Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.16% of the float of Cognition Therapeutics has been sold short.Short Interest Ratio / Days to CoverCognition Therapeutics has a short interest ratio ("days to cover") of 22.6, which indicates bearish sentiment.Change versus previous monthShort interest in Cognition Therapeutics has recently decreased by 1.53%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCognition Therapeutics does not currently pay a dividend.Dividend GrowthCognition Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 1 people have searched for CGTX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows2 people have added Cognition Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cognition Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders11.11% of the stock of Cognition Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.35% of the stock of Cognition Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cognition Therapeutics' insider trading history. Receive CGTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cognition Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CGTX Stock News HeadlinesCognition Set For Type C FDA Meeting In Oct '26 On Planned Phase 3 For Dementia Drug ZervimesineSeptember 29, 2026 | rttnews.comCognition Therapeutics Schedules FDA Type C Meeting to Discuss Phase 3 Trial Endpoint for Zervimesine in Dementia with Lewy BodiesSeptember 29, 2026 | quiverquant.comQLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.October 9 at 1:00 AM | InvestorPlace (Ad)Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLBSeptember 29, 2026 | globenewswire.comCognition Therapeutics to Present Zervimesine Development Progress at H.C. Wainwright Global Investment ConferenceSeptember 8, 2026 | quiverquant.comQCognition Therapeutics to Present at H.C. Wainwright Global Investment ConferenceSeptember 8, 2026 | globenewswire.comCognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business UpdateAugust 6, 2026 | markets.businessinsider.comCognition Therapeutics CEO Lisa Ricciardi to Participate in B. Riley Mind, Muscle & Vision Summit Fireside DiscussionJuly 13, 2026 | quiverquant.comQSee More Headlines CGTX Stock Analysis - Frequently Asked Questions How have CGTX shares performed this year? Cognition Therapeutics' stock was trading at $1.35 on January 1st, 2026. Since then, CGTX stock has decreased by 35.2% and is now trading at $0.8750. How were Cognition Therapeutics' earnings last quarter? Cognition Therapeutics, Inc. (NASDAQ:CGTX) issued its quarterly earnings data on Thursday, August, 6th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.02. When did Cognition Therapeutics IPO? Cognition Therapeutics (CGTX) raised $45 million in an initial public offering (IPO) on Thursday, October 7th 2021. The company issued 3,768,116 shares at a price of $11.00-$13.00 per share. How do I buy shares of Cognition Therapeutics? Shares of CGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cognition Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cognition Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Eli Lilly and Company (LLY), Meta Platforms (META), GE Aerospace (GE), Arista Networks (ANET) and Celestica (CLS). Company Calendar Last Earnings8/06/2026Today10/09/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CGTX's financial health is in the Yellow zone, according to TradeSmith. CGTX has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CGTX CIK1455365 Webwww.cogrx.com Phone412-481-2210FaxN/AEmployees14Year Founded2007Price Target and Rating Average Price Target for Cognition Therapeutics$3.33 High Price Target$4.00 Low Price Target$3.00 Potential Upside/Downside+280.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$23.49 million Net MarginsN/A Pretax MarginN/A Return on Equity-50.17% Return on Assets-40.22% Debt Debt-to-Equity RatioN/A Current Ratio7.03 Quick Ratio7.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.39 per share Price / Book2.25Miscellaneous Outstanding Shares95,090,000Free Float84,529,000Market Cap$83.38 million OptionableNot Optionable Beta1.80 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:CGTX) was last updated on 10/9/2026 by MarketBeat.com Staff. From Our PartnersThe IRA Mistake That Could Cost Americans 55+ Thousands in 2026JPMorgan has raised its 2026 gold forecast to $6,300, with a credible path to $8,000, and now calls gold a cor...Golden Crest Metals | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
